BioSpace News Archive

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data at the virtual 28th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 19 - 22, 2021.

Charles River Laboratories International, Inc. announced that it has divested its Research Models and Services operations in Japan and its gene therapy CDMO site in Sweden in two separate transactions.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced the pricing of an underwritten public offering of 13,207,547 shares of its common stock at a public offering price of $26.50 per share.

Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to approximately $7.8 million.

Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock.

The Jackson Laboratory, a U.S.-based nonprofit biomedical research institution, announced that it has acquired Charles River Laboratories Japan’s Research Models & Services business as a wholly owned subsidiary.

Everbridge , Inc. today announced its partnership with the COP26 World Climate Summit to present on the contributions of national early public warning solutions and critical event management (CEM) technology to unlocking resilience as a climate adaptation measure.

SYNAPS Dx, a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease, announces the close of its Series A $10 million investment, including private equity, individual and family funds, and corporate investors.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the development of the second generation version of its Rapid Neutralizing Antibody Test for COVID-19.